Premium
Controlled‐Release Iron Therapy in Pregnancy
Author(s) -
Symonds E. M.,
Radden H. S.,
Cellier K. M.
Publication year - 1969
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1969.tb02520.x
Subject(s) - medicine , pregnancy , significant difference , ferrous sulphate , gestation , iron therapy , double blind , obstetrics , ferrous , iron deficiency , anemia , chemistry , placebo , inorganic chemistry , genetics , alternative medicine , pathology , biology , organic chemistry
Summary One hundred and three antenatal patients with initial haemoglobin levels of 10.7 g./100 ml. or less at their first antenatal visit were treated with either ferrous gluconate, Ferrogradumet or intravenous Astrafer. A significant rise in haemoglobin level occurred in the first month in those groups receiving iron therapy compared with the control group. From the end of the first month until 36 weeks gestation, there was no significant difference between the treatment groups. A double‐blind trial in the Ferrogradumet group involving 52 patients over the first month of the trial showed no significant difference in side‐effects between the inert vehicle and the Ferrogradumet groups. Controlled‐release iron in the form of Ferrogradumet is a convenient and effective method of iron administration in pregnancy, both for prophylactic and therapeutic purposes.